DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,046 filers reported holding DANAHER CORPORATION in Q3 2016. The put-call ratio across all filers is 0.17 and the average weighting 0.5%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $3,878,573 | +3.4% | 15,633 | +0.0% | 0.99% | +6.8% |
Q2 2023 | $3,750,265 | +1.1% | 15,626 | +6.2% | 0.93% | -3.3% |
Q1 2023 | $3,709,803 | -7.2% | 14,719 | -2.2% | 0.96% | -9.3% |
Q4 2022 | $3,995,657 | -2.9% | 15,054 | -5.6% | 1.06% | -12.6% |
Q3 2022 | $4,117,000 | -3.6% | 15,941 | -5.3% | 1.21% | +2.2% |
Q2 2022 | $4,270,000 | -14.3% | 16,842 | -0.9% | 1.18% | -1.5% |
Q1 2022 | $4,983,000 | -11.2% | 16,987 | -0.4% | 1.20% | -7.8% |
Q4 2021 | $5,610,000 | +6.0% | 17,052 | -1.9% | 1.30% | -3.1% |
Q3 2021 | $5,292,000 | +10.0% | 17,382 | -3.0% | 1.35% | +12.7% |
Q2 2021 | $4,810,000 | +16.7% | 17,923 | -2.2% | 1.19% | +16.8% |
Q1 2021 | $4,123,000 | +0.7% | 18,319 | -0.7% | 1.02% | -5.8% |
Q4 2020 | $4,096,000 | +1.6% | 18,440 | -1.5% | 1.08% | -9.2% |
Q3 2020 | $4,030,000 | +21.2% | 18,714 | -0.5% | 1.20% | +12.5% |
Q2 2020 | $3,325,000 | +24.9% | 18,801 | -2.3% | 1.06% | -0.2% |
Q1 2020 | $2,662,000 | -28.7% | 19,235 | -20.9% | 1.06% | -8.8% |
Q4 2019 | $3,734,000 | -4.5% | 24,332 | -10.2% | 1.17% | -10.6% |
Q3 2019 | $3,911,000 | -12.3% | 27,082 | -13.3% | 1.30% | -12.4% |
Q2 2019 | $4,462,000 | +7.5% | 31,219 | -0.7% | 1.49% | +5.0% |
Q1 2019 | $4,150,000 | +25.8% | 31,435 | -1.7% | 1.42% | +12.5% |
Q4 2018 | $3,299,000 | -4.9% | 31,989 | +0.2% | 1.26% | +7.2% |
Q3 2018 | $3,470,000 | +8.0% | 31,931 | -1.9% | 1.18% | +2.6% |
Q2 2018 | $3,214,000 | +0.2% | 32,565 | -0.6% | 1.14% | -29.5% |
Q1 2018 | $3,206,000 | +4.7% | 32,750 | -0.8% | 1.62% | +8.0% |
Q4 2017 | $3,063,000 | +8.1% | 33,008 | -0.1% | 1.50% | +4.6% |
Q3 2017 | $2,833,000 | +1.9% | 33,035 | +0.3% | 1.44% | +15.1% |
Q2 2017 | $2,779,000 | -1.0% | 32,935 | +0.4% | 1.25% | -26.1% |
Q1 2017 | $2,806,000 | -2.3% | 32,810 | -11.1% | 1.69% | -0.7% |
Q4 2016 | $2,873,000 | -1.0% | 36,910 | -0.3% | 1.70% | -3.4% |
Q3 2016 | $2,902,000 | -22.5% | 37,024 | -0.1% | 1.76% | -21.7% |
Q2 2016 | $3,744,000 | +5.9% | 37,074 | -0.5% | 2.25% | +2.5% |
Q1 2016 | $3,534,000 | +2.1% | 37,259 | 0.0% | 2.20% | +1.8% |
Q4 2015 | $3,460,000 | +9.0% | 37,259 | 0.0% | 2.16% | +1.9% |
Q3 2015 | $3,174,000 | -2.3% | 37,259 | -1.8% | 2.12% | +11.7% |
Q2 2015 | $3,248,000 | -0.7% | 37,959 | -1.5% | 1.90% | -5.6% |
Q1 2015 | $3,272,000 | +1.0% | 38,542 | +1.9% | 2.01% | +0.7% |
Q4 2014 | $3,241,000 | +13.4% | 37,822 | +0.5% | 2.00% | +16.6% |
Q3 2014 | $2,858,000 | -3.2% | 37,622 | +0.3% | 1.71% | -4.3% |
Q2 2014 | $2,954,000 | +6.1% | 37,521 | +1.1% | 1.79% | -1.7% |
Q1 2014 | $2,784,000 | -2.0% | 37,121 | +0.9% | 1.82% | -1.2% |
Q4 2013 | $2,840,000 | +11.1% | 36,796 | -0.3% | 1.84% | +4.5% |
Q3 2013 | $2,557,000 | +8.8% | 36,896 | -0.7% | 1.76% | +8.5% |
Q2 2013 | $2,351,000 | – | 37,138 | – | 1.63% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
Third Point | 2,450,000 | $607,845,000 | 9.22% |
Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |